Clinical trials: DED
Dry Eye
A Study to Evaluate AXR-159 Ophthalmic Solution in Patients With Dry Eye Disease
Protocol AXR201701 is a multicenter, double-masked, vehicle-controlled, randomized, parallel group study carried out in 2 stages (Stage 1: AXR-159 Ophthalmic Solution (30 mg/mL or 50 mg/mL); Stage 2: AXR-159 Ophthalmic Solution…
- Trial name
- NCT03598699
- Testing
- AXR-159, Vehicle
- Where
- 3 sites in United States
- Volunteers
- 102 people
- Sponsor
- AxeroVision, Inc.
Dry Eye Disease (DED)
Effects of NOV03 on the Tear Film
Determine the effect of a single instillation of NOV03 on the thickness and evaporation rate of the mucus-aqueous layer of the tear film
- Trial name
- NCT05723770
- Testing
- instillation of NOV03
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Bausch & Lomb Incorporated
Dry Eye Disease
The Utility of IVCM to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With DED
This research study is looking to see if in vivo confocal microscopy (IVCM) imaging can be used to confirm clinical findings (which are noted by the doctor during an eye exam) and measure the immune response to the inflammation…
- Trial name
- NCT02120079
- Testing
- Lotemax, Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears), In Vivo Confocal Microscopy (IVCM)
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Tufts Medical Center
Dry Eye Disease
Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-CSI in Subjects With Dry Eye Disease.
To assess the safety, tolerability and efficacy of a single dose of OTX-CSI, a sustained release cyclosporine drug product, in subjects with dry eye disease.
- Trial name
- NCT04362670
- Testing
- OTX-CSI
- Where
- 15 sites in United States
- Volunteers
- 153 people
- Sponsor
- Ocular Therapeutix, Inc.
Dry Eye Disease (DED)
Efficacy and Safety of a New Artificial Tear Formulation Compared With Systane Ultra Multidose in Participants With Dry Eye Disease
The purpose of this study is to compare the efficacy and safety of a new artificial tear formulation (011516X) with Systane® Ultra Multidose for 90 days in participants with Dry Eye Disease (DED).
- Trial name
- NCT04393441
- Testing
- 011516X (New Artificial Tear Formulation), Systane Ultra Multidose, REFRESH PLUS®
- Where
- 26 sites in United States
- Volunteers
- 400 people
- Sponsor
- Allergan
Dry Eye
Performance and Safety of T2769 in DED
To demonstrate the non-inferiority of T2769 compared to Vismed® Multi in terms of total ocular surface staining (Oxford score) after 35 days of treatment. To evaluate the performance and safety of T2769 versus Vismed® Multi.
- Trial name
- NCT05965778
- Testing
- T2769, Vismed® Multi
- Where
- France
- Volunteers
- 251 people
- Sponsor
- Laboratoires Thea
Dry Eye
Study to Evaluate the Safety and Efficacy of SDP-4 in Subjects With Dry Eye Disease (DED)
SDP-4-CS201, is a Phase 2, multi-center, double-masked, randomized, vehicle-controlled, dose-response, parallel-group study designed to evaluate the ocular and systemic safety and efficacy of SDP-4 ophthalmic solution in subjects…
- Trial name
- SDP-4-CS201 (NCT03889886)
- Testing
- SDP-4 Ophthalmic Solution (0.1%), SDP-4 Ophthalmic Solution (1.0%), SDP-4 Ophthalmic Solution (3.0%)
- Where
- 26 sites in United States
- Volunteers
- 305 people
- Sponsor
- Silk Technologies, Ltd.
Kerato Conjunctivitis Sicca
Safety and Efficacy of KPI-121 in Subjects With DED
The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease.
- Trial name
- STRIDE 3 (NCT03616899)
- Testing
- KPI-121 Ophthalmic Suspension, Vehicle
- Where
- 81 sites in United States
- Volunteers
- 901 people
- Sponsor
- Kala Pharmaceuticals, Inc.
Dry Eye Disease
CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
The objective of this study is to assess the efficacy, safety, and tolerability of CyclASol Ophthalmic Solution in comparison to vehicle for the treatment of the signs and symptoms of DED.
- Trial name
- NCT03292809
- Testing
- CyclASol topical ocular, eye drops, Vehicle topical ocular, eye drops
- Where
- 9 sites in United States
- Volunteers
- 328 people
- Sponsor
- Novaliq GmbH
Dry Eye
Dry Eye Disease Study With Brimonidine
To evaluate the tolerability and preliminary efficacy of Brimonidine eye drops (with and without corticosteroid eye drops) for the treatment of Dry Eye Disease (DED).
- Trial name
- NCT03418727
- Testing
- Brimonidine, Brimonidine Mono Therapy, sodium carboxymethylcellulose
- Where
- 3 sites in United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Ocugen
Dry Eye Disease (DED)
CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease in Subjects Who Completed CYS-004
The objective of this trial is to evaluate safety and tolerability of CyclASol during long-term use in subjects with Dry Eye Disease.
- Trial name
- NCT04523142
- Testing
- CyclASol Ophthalmic Solution
- Where
- 14 sites in United States
- Volunteers
- 202 people
- Sponsor
- Novaliq GmbH
Dry Eye Disease (DED)
Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study)
The objectives of this trial are to evaluate the safety and tolerability of perfluorohexyloctane (NOV03) ophthalmic solution during long-term use in subjects with Dry Eye Disease (DED) associated with MGD (Meibomian Gland…
- Trial name
- NCT04140227
- Testing
- NOV03
- Where
- 28 sites in United States
- Volunteers
- 256 people
- Sponsor
- Bausch & Lomb Incorporated
Dry Eye Disease
ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
The objective of this pivotal trial is to assess the efficacy, safety and tolerability of CyclASol in comparison to the vehicle for the treatment of signs and symptoms of Dry Eye Disease (DED).
- Trial name
- NCT04523129
- Testing
- CyclASol topical ocular, eye drops, Vehicle topical ocular, eye drops
- Where
- 27 sites in United States
- Volunteers
- 834 people
- Sponsor
- Novaliq GmbH
Meibomian Gland Dysfunction, Dry Eye
A Multicenter Study Evaluating AZR-MD-001 in Patients With Meibomian Gland Dysfunction and Evaporative Dry Eye Disease (DED)
AZ201801 is a multicenter study of AZR-MD-001 ointment and AZR-MD-001 vehicle in patients with Meibomian Gland Dysfunction (MGD) and evaporative Dry Eye Disease (DED)
- Trial name
- NCT03652051
- Testing
- AZR-MD-001 Low Dose, AZR-MD-001 Mid Dose, AZR-MD-001 High Dose
- Where
- 30 sites in Australia, Canada and 1 more
- Volunteers
- 321 people
- Sponsor
- Azura Ophthalmics
Dry Eye Disease
A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease.
Primary objective To evaluate the efficacy of 5 μg/mL and 10 μg/mL concentrations of the new formulation of rhNGF ophthalmic solution versus vehicle, in order to demonstrate superiority of at least 1 of the concentrations over…
- Trial name
- REDUCO (NCT06244316)
- Testing
- rhNGF 5 μg/mL, rhNGF 10 μg/mL
- Where
- 14 sites in United States, Italy
- Volunteers
- 317 people
- Sponsor
- Dompé Farmaceutici S.p.A
Dry Eye Syndromes
CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)
The objective of this study was to compare the safety, efficacy, and tolerability of two different dose levels of CyclASol Ophthalmic Solutions to placebo (vehicle) and Restasis for the treatment of the signs and symptoms of Dry…
- Trial name
- NCT02617667
- Testing
- Cyclosporine A
- Where
- 4 sites in United States
- Volunteers
- 207 people
- Sponsor
- Novaliq GmbH
Dry Eye
Study of Brimonidine Tartrate Nanoemulsion Eye Drop Solution in the Treatment of Dry Eye Disease (DED)
This study evaluates the use of Brimonidine tartrate nanoemulsion eye drop solution in the treatment of Dry Eye Disease (DED). Half of participants will receive Brimonidine and half will receive ophthalmic buffered saline…
- Trial name
- NCT03785340
- Testing
- Brimonidine Tartrate
- Where
- 16 sites in United States
- Volunteers
- 252 people
- Sponsor
- Ocugen
Dry Eye
Study to Evaluate the Efficacy of SDP-4 in Subjects With Dry Eye Disease (DED) (SDP-4-CS202)
SDP-4-CS202 is a Phase 2, multicenter, double-masked, randomized, vehicle-controlled, parallel group study designed to evaluate the ocular efficacy of SDP-4 ophthalmic solution in subjects with moderate to severe dry eye disease…
- Trial name
- NCT04535947
- Testing
- Vehicle, SDP-4 Ophthalmic Solution (1.0%)
- Where
- 5 sites in United States
- Volunteers
- 153 people
- Sponsor
- Silk Technologies, Ltd.
Keratitis
Effect of IKERVIS® Eye Drops Once Daily on the Quality of Vision in Dry Eye Disease Patients With Severe Keratitis
The proposed 3-month study is a prospective, open-label, multicentre, phase IV, proof of concept study. The study is designed to assess the effect on the quality of vision of IKERVIS® (1mg/mL ciclosporin) eye drops administered…
- Trial name
- FAST (NCT03237936)
- Testing
- 1mg/mL ciclosporin
- Where
- France
- Volunteers
- 17 people
- Sponsor
- Santen SAS
Dry Eye Disease, Endothelial Cell
A Clinical Trial to Evaluate the Corneal Endothelial Health of DED Subjects Treated With Cyclosporine
The objective of this trial is to evaluate the effect of cyclosporine ophthalmic solution, 0.1% on corneal endothelial cell health in comparison to a hypotonic saline solution in subjects with Dry Eye Disease (DED)
- Trial name
- NCT06329661
- Testing
- Cyclosporine ophthalmic solution, 0.1%, Saline solution, 0.6%
- Where
- 6 sites in United States
- Volunteers
- 204 people
- Sponsor
- Novaliq GmbH